Consequently, the recommended treatment approach for patients with advanced or metastatic BRAF-mutated melanoma is now a combination of a BRAF inhibitor and a MAPK kinase (MEK) inhibitor [7,8]. The gene discussed is BRAF; the disease is melanoma.